

# Press Release

For further information:

Peter Friedli  
Neuhofstrasse 8  
8834 Schindellegi  
Tel: 044/283 29 00  
Email: peter.friedli@friedlicorp.ch

## New Venturetec with a gain for the period October 1, 2009 to March 31, 2010

### Results for the six months period ending March 31, 2010

Zug, May 19, 2010. New Venturetec closed the first six months for fiscal year 2009/10, ended March 31, 2010, with a gain of USD 4,830,258 compared with a loss of USD 51,453,598 in the same period 2008/09. The net asset value per share increased from USD 6.14 to USD 8.09 which equals 31.76% during the reporting six month period. The share price in the same period decreased from CHF 5.08 to CHF 4.57, or -10.04%.

The waiver of USD 4'970'034 accrued management fee by Peter Friedli and the Investment Manager on November 4, 2009 had no impact on the profit of the Company as it was recognized directly through equity as part of additional paid-in capital.

The reasons for the profit is the share price of Osiris Therapeutics which increased by 11.11% in the reporting period, and the higher valuation of the Invenda position. The valuation of the remaining portfolio companies did not change materially in the reporting period as their valuations have been adjusted to the economic environment in the prior fiscal year. The details on the valuation of the privately held companies are described in the semi-annual report.

As of March 31, 2010, New Venturetec had six investments with two investments valued higher than the investment costs and four below investment costs. The total value of investments is USD 60,517,521 which results in an unrealized loss of USD 39,539,435 against the costs of the investments. As of March 31, 2010, 71.59% of the total investments are in biotechnology and 28.41% in technology. The largest position is Osiris Therapeutics (NASDAQ:OSIR) with 50.54% of total investments.

There was no board remuneration paid for the reporting period but rather accrued. The management fee for the reporting period was USD 150,558 of which USD 97,466 were paid. Total operational costs for the first half of the fiscal year 2009/10 were USD 199,869.

The semi-annual report, including financial statements for the reporting period can be downloaded from [www.newventuretec.com/Semi-AnnualReport2010.pdf](http://www.newventuretec.com/Semi-AnnualReport2010.pdf).

New Venturetec is a publicly traded Swiss investment company (SIX:NEV) which invests directly in venture capital companies predominantly in the USA in the areas of biotechnology and technology.